Doudican Nicole A, Wen Shih Ya, Mazumder Amitabha, Orlow Seth J
1The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.
J Biomol Screen. 2014 Apr;19(4):575-84. doi: 10.1177/1087057113517549. Epub 2013 Dec 26.
Disruption of protein processing in the secretory pathway is a measurable hallmark of endoplasmic reticulum (ER) stress. Activation of ER stress-mediated pathways has been implicated in numerous diseases, including cancer. To identify agents that induce ER stress, we established a screen for compounds that reduce secretion of the reporter protein Gaussia luciferase (GLUC). Given the clinically validated importance of targeting ER stress-mediated pathways in the treatment of multiple myeloma (MM), we used this hematological malignancy as a model for validating our screening system. From a screen of 2000 marketed drugs and natural compounds in KMS11 and ARP1 MM cells, we identified 97 agents that reduced GLUC secretion in both cell lines by at least 30%. To confirm inducers of ER stress, we applied a secondary screen that assessed splicing of the unfolded protein response (UPR) transcription factor XBP1. One agent, theaflavin-3,3'-digallate (TF-3), was chosen based on its history of safe human consumption and further validated through studies of ER stress-related pathways, including the UPR and apoptosis. Given these promising results, this screen could be a useful tool to identify agents targeting ER stress-related mechanisms in other cellular systems wherein ER stress plays a role in disease etiology.
分泌途径中蛋白质加工的破坏是内质网(ER)应激的一个可测量的标志。ER应激介导的信号通路的激活与包括癌症在内的多种疾病有关。为了鉴定诱导ER应激的药物,我们建立了一个筛选系统,用于筛选能够降低报告蛋白高斯荧光素酶(GLUC)分泌的化合物。鉴于在多发性骨髓瘤(MM)治疗中靶向ER应激介导的信号通路具有临床验证的重要性,我们将这种血液系统恶性肿瘤作为验证我们筛选系统的模型。通过对KMS11和ARP1 MM细胞系中的2000种上市药物和天然化合物进行筛选,我们鉴定出97种药物,它们在两种细胞系中均使GLUC分泌减少至少30%。为了确认ER应激诱导剂,我们应用了二级筛选,评估未折叠蛋白反应(UPR)转录因子XBP1的剪接。基于其在人体安全使用的历史,选择了一种药物,茶黄素-3,3'-双没食子酸酯(TF-3),并通过对包括UPR和凋亡在内的ER应激相关信号通路的研究进一步验证。鉴于这些有前景的结果,该筛选系统可能是一种有用的工具,用于在ER应激在疾病病因学中起作用的其他细胞系统中鉴定靶向ER应激相关机制的药物。